{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:24:29Z","timestamp":1785403469585,"version":"3.56.0"},"reference-count":130,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Innovations in genomics, epigenomics, and transcriptomics now lay the groundwork for therapeutic interventions against neoplastic disease. In the past 30 years, the molecular pathogenesis of pituitary adenomas has been characterized. This enhanced understanding of the biology of pituitary tumors has potential to impact current treatment paradigms, and there exists significant translational potential for these results. In this review the authors summarize the results of genomics and molecular biology investigations into pituitary adenoma pathogenesis and behavior and discuss opportunities to translate basic science findings into clinical benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The authors searched the PubMed and MEDLINE databases by using combinations of the keywords \u201cpituitary adenoma,\u201d \u201cgenomics,\u201d \u201cpathogenesis,\u201d and \u201cepigenomics.\u201d From the initial search, additional articles were individually evaluated and selected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Pituitary adenoma growth is primarily driven by unrestrained cell cycle progression, deregulation of growth and proliferation pathways, and abnormal epigenetic regulation of gene expression. These pathways may be amenable to therapeutic intervention. A significant number of studies have attempted to establish links between gene mutations and tumor progression, but a thorough mechanistic understanding remains elusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Although not currently a prominent aspect in the clinical management of pituitary adenomas, genomics and epigenomic studies may become essential in refining patient care and developing novel pharmacological agents. Future basic science investigations should aim at elucidating mechanistic understandings unique to each pituitary adenoma subtype, which will facilitate rational drug design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2020.3.focus20104","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T08:21:59Z","timestamp":1591172519000},"page":"E11","source":"Crossref","is-referenced-by-count":19,"title":["Genomic and molecular characterization of pituitary adenoma pathogenesis: review and translational opportunities"],"prefix":"10.3171","volume":"48","author":[{"given":"Mazin","family":"Elsarrag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parantap D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Chatrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Jane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1","series-title":"J Neurol Surg B Skull Base","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-0036-1598022","article-title":"Cavernous sinus involvement by pituitary adenomas: clinical implications and outcomes of endoscopic endonasal resection","volume":"78","author":"Ajlan A","year":"2017","unstructured":"Ajlan A, Achrol AS, Albakr A, Feroze AH, Westbroek EM, Hwang P, : Cavernous sinus involvement by pituitary adenomas: clinical implications and outcomes of endoscopic endonasal resection. J Neurol Surg B Skull Base 78:273\u2013282, 201710.1055\/s-0036-159802228603683"},{"key":"b2","series-title":"J Clin Invest","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1172\/JCI114705","article-title":"Clinically nonfunctioning pituitary tumors are monoclonal in origin","volume":"86","author":"Alexander JM","year":"1990","unstructured":"Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A, Klibanski A: Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 86:336\u2013340, 1990197317410.1172\/JCI114705"},{"key":"b3","series-title":"Pituitary","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11102-019-00981-9","article-title":"Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers","volume":"22","author":"Almeida JP","year":"2019","unstructured":"Almeida JP, Stephens CC, Eschbacher JM, Felicella MM, Yuen KCJ, White WL, : Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary 22:514\u2013519, 201910.1007\/s11102-019-00981-9"},{"key":"b4","series-title":"J Clin Endocrinol Metab","first-page":"3210","article-title":"The MEN-1 gene is rarely down-regulated in pituitary adenomas","volume":"83","author":"Asa SL","year":"1998","unstructured":"Asa SL, Somers K, Ezzat S: The MEN-1 gene is rarely down-regulated in pituitary adenomas. J Clin Endocrinol Metab 83:3210\u20133212, 19989745428"},{"key":"b5","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas","volume":"91","author":"Batista DL","year":"2006","unstructured":"Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, : The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482\u20134488, 200610.1210\/jc.2006-124516940446"},{"key":"b6","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1158\/1078-0432.CCR-16-0790","article-title":"Landscape of genomic alterations in pituitary adenomas","volume":"23","author":"Bi WL","year":"2017","unstructured":"Bi WL, Horowitz P, Greenwald NF, Abedalthagafi M, Agarwalla PK, Gibson WJ, : Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res 23:1841\u20131851, 201710.1158\/1078-0432.CCR-16-079027707790"},{"key":"b7","series-title":"Horm Metab Res","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1055\/s-0034-1383566","article-title":"Expression analysis of GADD45\u03b3, MEG3, and p8 in pituitary adenomas","volume":"46","author":"Binse I","year":"2014","unstructured":"Binse I, Ueberberg B, Sandalcioglu IE, Flitsch J, Luedecke DK, Mann K, : Expression analysis of GADD45\u03b3, MEG3, and p8 in pituitary adenomas. Horm Metab Res 46:644\u2013650, 20142512686110.1055\/s-0034-1383566"},{"key":"b8","series-title":"Front Oncol","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fonc.2014.00203","article-title":"Genetically engineered mouse models of pituitary tumors","volume":"4","author":"Cano DA","year":"2014","unstructured":"Cano DA, Soto-Moreno A, Leal-Cerro A: Genetically engineered mouse models of pituitary tumors. Front Oncol 4:203, 201410.3389\/fonc.2014.0020325136513"},{"key":"b9","series-title":"Mol Cell Endocrinol","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2016.10.005","article-title":"Stem cells and their role in pituitary tumorigenesis","volume":"445","author":"Carreno G","year":"2017","unstructured":"Carreno G, Gonzalez-Meljem JM, Haston S, Martinez-Barbera JP: Stem cells and their role in pituitary tumorigenesis. Mol Cell Endocrinol 445:27\u201334, 201710.1016\/j.mce.2016.10.00527720895"},{"key":"b10","series-title":"Ann Endocrinol (Paris)","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ando.2015.04.002","article-title":"Management of clinically non-functioning pituitary adenoma","volume":"76","author":"Chanson P","year":"2015","unstructured":"Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S: Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 76:239\u2013247, 201510.1016\/j.ando.2015.04.002"},{"key":"b11","series-title":"J Transl Med","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s12967-019-02148-3","article-title":"Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles","volume":"17","author":"Cheng S","year":"2019","unstructured":"Cheng S, Xie W, Miao Y, Guo J, Wang J, Li C, : Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles. J Transl Med 17:407, 20193179605210.1186\/s12967-019-02148-3"},{"key":"b12","series-title":"Brain Pathol","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1750-3639.2001.tb00402.x","article-title":"Clonality of pituitary tumours: more complicated than initially envisaged?","volume":"11","author":"Clayton RN","year":"2001","unstructured":"Clayton RN, Farrell WE: Clonality of pituitary tumours: more complicated than initially envisaged? Brain Pathol 11:313\u2013327, 200110.1111\/j.1750-3639.2001.tb00402.x11414474"},{"key":"b13","series-title":"Front Horm Res","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000079045","article-title":"Pituitary tumour clonality revisited","volume":"32","author":"Clayton RN","year":"2004","unstructured":"Clayton RN, Farrell WE: Pituitary tumour clonality revisited. Front Horm Res 32:186\u2013204, 200410.1159\/00007904515281347"},{"key":"b14","series-title":"Clin Cancer Res","first-page":"3973","article-title":"Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins","volume":"6","author":"Clayton RN","year":"2000","unstructured":"Clayton RN, Pfeifer M, Atkinson AB, Belchetz P, Wass JA, Kyrodimou E, : Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins. Clin Cancer Res 6:3973\u20133982, 200011051246"},{"key":"b15","series-title":"Oncotarget","doi-asserted-by":"publisher","first-page":"19674","DOI":"10.18632\/oncotarget.14936","article-title":"O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis","volume":"8","author":"Dai C","year":"2017","unstructured":"Dai C, Sun B, Liu X, Bao X, Feng M, Yao Y, : O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis. Oncotarget 8:19674\u201319683, 201710.18632\/oncotarget.1493628152515"},{"key":"b16","series-title":"Endocr Pathol","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12022-019-09587-0","article-title":"The genomic landscape of sporadic prolactinomas","volume":"30","author":"De Sousa SMC","year":"2019","unstructured":"De Sousa SMC, Wang PPS, Santoreneos S, Shen A, Yates CJ, Babic M, : The genomic landscape of sporadic prolactinomas. Endocr Pathol 30:318\u2013328, 20193147391710.1007\/s12022-019-09587-0"},{"key":"b17","series-title":"Eur J Endocrinol","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange E","year":"2015","unstructured":"Delgrange E, Vasiljevic A, Wierinckx A, Fran\u00e7ois P, Jouanneau E, Raverot G, : Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172:791\u2013801, 20152579237610.1530\/EJE-14-0990"},{"key":"b18","series-title":"Front Neuroendocrinol","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1006\/frne.1999.0195","article-title":"Molecular pathogenesis of pituitary tumors","volume":"21","author":"Farrell WE","year":"2000","unstructured":"Farrell WE, Clayton RN: Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol 21:174\u2013198, 200010.1006\/frne.1999.019510882539"},{"key":"b19","series-title":"Br J Cancer","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/sj.bjc.6690319","article-title":"Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours","volume":"80","author":"Farrell WE","year":"1999","unstructured":"Farrell WE, Simpson DJ, Bicknell J, Magnay JL, Kyrodimou E, Thakker RV, : Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. Br J Cancer 80:44\u201350, 199910.1038\/sj.bjc.669031910389976"},{"key":"b20","series-title":"Clin Endocrinol (Oxf)","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","author":"Fougner SL","year":"2008","unstructured":"Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J: The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 68:458\u2013465, 200810.1111\/j.1365-2265.2007.03065.x"},{"key":"b21","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto F","year":"2013","unstructured":"Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, : Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab 98:E66\u2013E71, 201310.1210\/jc.2012-260923118420"},{"key":"b22","series-title":"Pituitary","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","article-title":"Prevalence and incidence of pituitary adenomas: a population based study in Malta","volume":"16","author":"Gruppetta M","year":"2013","unstructured":"Gruppetta M, Mercieca C, Vassallo J: Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16:545\u2013553, 20132323904910.1007\/s11102-012-0454-0"},{"key":"b23","series-title":"J Endocrinol","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-17-0258","article-title":"Stem\/progenitor cells in pituitary organ homeostasis and tumourigenesis","volume":"236","author":"Haston S","year":"2018","unstructured":"Haston S, Manshaei S, Martinez-Barbera JP: Stem\/progenitor cells in pituitary organ homeostasis and tumourigenesis. J Endocrinol 236:R1\u2013R13, 20182885531610.1530\/JOE-17-0258"},{"key":"b24","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1210\/jcem-71-6-1427","article-title":"Clonal origin of pituitary adenomas","volume":"71","author":"Herman V","year":"1990","unstructured":"Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S: Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71:1427\u20131433, 1990197775910.1210\/jcem-71-6-1427"},{"key":"b25","series-title":"Clin Cancer Res","first-page":"2133","article-title":"Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors","volume":"5","author":"Hibberts NA","year":"1999","unstructured":"Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, : Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res 5:2133\u20132139, 199910473097"},{"key":"b26","series-title":"Eur J Endocrinol","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland LJ","year":"2005","unstructured":"Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, : The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645\u2013654, 20051581792210.1530\/eje.1.01876"},{"key":"b27","series-title":"Cancer Res Treat","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4143\/crt.2016.017","article-title":"Inhibition of SKP2 sensitizes bromocriptine-induced apoptosis in human prolactinoma cells","volume":"49","author":"Huang J","year":"2017","unstructured":"Huang J, Zhang F, Jiang L, Hu G, Sun W, Zhang C, : Inhibition of SKP2 sensitizes bromocriptine-induced apoptosis in human prolactinoma cells. Cancer Res Treat 49:358\u2013373, 201710.4143\/crt.2016.01727488872"},{"key":"b28","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3171\/jns.1990.73.5.0731","article-title":"Clonal origin of pituitary adenomas","volume":"73","author":"Jacoby LB","year":"1990","unstructured":"Jacoby LB, Hedley-Whyte ET, Pulaski K, Seizinger BR, Martuza RL: Clonal origin of pituitary adenomas. J Neurosurg 73:731\u2013735, 1990221316310.3171\/jns.1990.73.5.0731"},{"key":"b29","series-title":"Endocr Relat Cancer","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1530\/ERC-12-0322","article-title":"Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations","volume":"20","author":"Jaffrain-Rea ML","year":"2013","unstructured":"Jaffrain-Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, : Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer 20:753\u2013766, 201310.1530\/ERC-12-032223940012"},{"key":"b30","series-title":"J Endocrinol Invest","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40618-018-0963-4","article-title":"Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1","volume":"42","author":"Jian M","year":"2019","unstructured":"Jian M, Du Q, Zhu D, Mao Z, Wang X, Feng Y, : Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1. J Endocrinol Invest 42:639\u2013652, 201910.1007\/s40618-018-0963-430370446"},{"key":"b31","series-title":"Endocrinol Metab (Seoul)","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3803\/EnM.2013.28.4.245","article-title":"The molecular pathogenesis of pituitary adenomas: an update","volume":"28","author":"Jiang X","year":"2013","unstructured":"Jiang X, Zhang X: The molecular pathogenesis of pituitary adenomas: an update. Endocrinol Metab (Seoul) 28:245\u2013254, 201310.3803\/EnM.2013.28.4.245"},{"key":"b32","series-title":"Pharmacoeconomics","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00019053-200018010-00008","article-title":"The impact of pituitary adenoma on morbidity. Increased sick leave and disability retirement in a cross-sectional analysis of Swedish national data","volume":"18","author":"Jonsson B","year":"2000","unstructured":"Jonsson B, Nilsson B: The impact of pituitary adenoma on morbidity. Increased sick leave and disability retirement in a cross-sectional analysis of Swedish national data. Pharmacoeconomics 18:73\u201381, 200010.2165\/00019053-200018010-00008"},{"key":"b33","series-title":"Endocr Relat Cancer","doi-asserted-by":"publisher","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki L","year":"2012","unstructured":"Kasuki L, Vieira Neto L, Wildemberg LEA, Colli LM, de Castro M, Takiya CM, : AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer 19:L25\u2013L29, 20122242000410.1530\/ERC-12-0020"},{"key":"b34","series-title":"Int J Endocrinol","first-page":"2014","article-title":"MicroRNAs in human pituitary adenomas","volume":"435171","author":"Li XH","year":"2014","unstructured":"Li XH, Wang EL, Zhou HM, Yoshimoto K, Qian ZR: MicroRNAs in human pituitary adenomas. Int J Endocrinol 2014:435171, 2014"},{"key":"b35","series-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd RV","year":"2017","unstructured":"Lloyd RV, Osamura YR, Kloppel G, Rosai J: WHO Classification of Tumours of Endocrine Organs, ed 4. World Health Organization, 2017"},{"key":"b36","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/cncr.10676","article-title":"Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas","volume":"95","author":"Ma W","year":"2002","unstructured":"Ma W, Ikeda H, Yoshimoto T: Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 95:258\u2013266, 200210.1002\/cncr.1067612124824"},{"key":"b37","series-title":"Zhonghua Yi Xue Za Zhi","first-page":"1382","article-title":"[Clinicopathology, clonality, and hormone production profile of prolactinoma.]","volume":"85","author":"Ma WB","year":"2005","unstructured":"Ma WB, Ikeda H, Yoshimoto T: [Clinicopathology, clonality, and hormone production profile of prolactinoma.] Zhonghua Yi Xue Za Zhi 85:1382\u20131387, 2005 (Chinese)16029648"},{"key":"b38","series-title":"Neuropathol Appl Neurobiol","article-title":"Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint","author":"Manojlovic-Gacic E","unstructured":"Manojlovic-Gacic E, Bollerslev J, Casar-Borota O: Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint. Neuropathol Appl Neurobiol [epub ahead of print], 201931112312"},{"key":"b39","series-title":"Nat Rev Endocrinol","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/nrendo.2011.40","article-title":"Pathogenesis of pituitary tumors","volume":"7","author":"Melmed S","year":"2011","unstructured":"Melmed S: Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7:257\u2013266, 20112142324210.1038\/nrendo.2011.40"},{"key":"b40","series-title":"Endocr Pathol","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO Classification of Pituitary Tumors","volume":"28","author":"Mete O","year":"2017","unstructured":"Mete O, Lopes MB: Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol 28:228\u2013243, 20172876605710.1007\/s12022-017-9498-z"},{"key":"b41","series-title":"Pituitary","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11102-011-0340-1","article-title":"Expression of cell growth negative regulators MEG3 and GADD45\u03b3 is lost in most sporadic human pituitary adenomas","volume":"15","author":"Mezzomo LC","year":"2012","unstructured":"Mezzomo LC, Gonzales PH, Pesce FG, Kretzmann Filho N, Ferreira NP, Oliveira MC, : Expression of cell growth negative regulators MEG3 and GADD45\u03b3 is lost in most sporadic human pituitary adenomas. Pituitary 15:420\u2013427, 201210.1007\/s11102-011-0340-121850407"},{"key":"b42","series-title":"Front Horm Res","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000079037","article-title":"Cell cycle dysregulation in pituitary oncogenesis","volume":"32","author":"Mu\u015fat M","year":"2004","unstructured":"Mu\u015fat M, Vax VV, Borboli N, Gueorguiev M, Bonner S, Korbonits M, : Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res 32:34\u201362, 200410.1159\/00007903715281339"},{"key":"b43","series-title":"Brain Tumor Pathol","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10014-017-0307-7","article-title":"New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors","volume":"35","author":"Nishioka H","year":"2018","unstructured":"Nishioka H, Inoshita N: New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol 35:57\u201361, 20182931839610.1007\/s10014-017-0307-7"},{"key":"b44","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/jnen\/64.5.398","article-title":"The p15INK4b\/p16INK4a\/RB1 pathway is frequently deregulated in human pituitary adenomas","volume":"64","author":"Ogino A","year":"2005","unstructured":"Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, : The p15INK4b\/p16INK4a\/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 64:398\u2013403, 200510.1093\/jnen\/64.5.398"},{"key":"b45","series-title":"Front Horm Res","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000079036","article-title":"Molecular pathology of the pituitary. Development and functional differentiation of pituitary adenomas","volume":"32","author":"Osamura RY","year":"2004","unstructured":"Osamura RY, Egashira N, Miyai S, Yamazaki M, Takekoshi S, Sanno N, : Molecular pathology of the pituitary. Development and functional differentiation of pituitary adenomas. Front Horm Res 32:20\u201333, 200410.1159\/00007903615281338"},{"key":"b46","series-title":"Histochem Cell Biol","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00418-008-0472-1","article-title":"Pathology of the human pituitary adenomas","volume":"130","author":"Osamura RY","year":"2008","unstructured":"Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, : Pathology of the human pituitary adenomas. Histochem Cell Biol 130:495\u2013507, 20081868863610.1007\/s00418-008-0472-1"},{"key":"b47","series-title":"Endocrine","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","article-title":"Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial","volume":"57","author":"Petersenn S","year":"2017","unstructured":"Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, : Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 57:156\u2013165, 20172859719810.1007\/s12020-017-1316-3"},{"key":"b48","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1210\/jcem.83.4.4859","article-title":"Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors","volume":"83","author":"Prezant TR","year":"1998","unstructured":"Prezant TR, Levine J, Melmed S: Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab 83:1388\u20131391, 1998954317210.1210\/jcem.83.4.4859"},{"key":"b49","series-title":"Nat Genet","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease","volume":"47","author":"Reincke M","year":"2015","unstructured":"Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, : Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47:31\u201338, 20152548583810.1038\/ng.3166"},{"key":"b50","series-title":"Eur J Endocrinol","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-15-1064","article-title":"Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas","volume":"174","author":"Ronchi CL","year":"2016","unstructured":"Ronchi CL, Peverelli E, Herterich S, Weigand I, Mantovani G, Schwarzmayr T, : Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 174:363\u2013372, 201610.1530\/EJE-15-106426701869"},{"key":"b51","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/1078-0432.CCR-17-2206","article-title":"The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing\u2019s disease and endocrine-inactive subtypes","volume":"24","author":"Salomon MP","year":"2018","unstructured":"Salomon MP, Wang X, Marzese DM, Hsu SC, Nelson N, Zhang X, : The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing\u2019s disease and endocrine-inactive subtypes. Clin Cancer Res 24:4126\u20134136, 201810.1158\/1078-0432.CCR-17-220630084836"},{"key":"b52","series-title":"J Clin Endocrinol Metab","first-page":"1675","article-title":"Genetic basis of endocrine disease: pituitary tumor pathogenesis","volume":"82","author":"Shimon I","year":"1997","unstructured":"Shimon I, Melmed S: Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab 82:1675\u20131681, 19979177361"},{"key":"b53","series-title":"Carcinogenesis","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/carcin\/22.8.1149","article-title":"Aberrant expression of G1\/S regulators is a frequent event in sporadic pituitary adenomas","volume":"22","author":"Simpson DJ","year":"2001","unstructured":"Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN, : Aberrant expression of G1\/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 22:1149\u20131154, 200110.1093\/carcin\/22.8.1149"},{"key":"b54","series-title":"Int J Oncol","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3892\/ijo.2017.4120","article-title":"Trophic and neurotrophic factors in human pituitary adenomas (Review)","volume":"51","author":"Spoletini M","year":"2017","unstructured":"Spoletini M, Taurone S, Tombolini M, Minni A, Altissimi G, Wierzbicki V, : Trophic and neurotrophic factors in human pituitary adenomas (Review). Int J Oncol 51:1014\u20131024, 20172890235010.3892\/ijo.2017.4120"},{"key":"b55","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1023\/A:1010655419332","article-title":"Genetic basis of pituitary adenoma invasiveness: a review","volume":"52","author":"Suhardja A","year":"2001","unstructured":"Suhardja A, Kovacs K, Rutka J: Genetic basis of pituitary adenoma invasiveness: a review. J Neurooncol 52:195\u2013204, 200110.1023\/A:101065541933211519849"},{"key":"b56","series-title":"Clin Med Res","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3121\/cmr.4.2.130","article-title":"The emerging role of pituitary tumor transforming gene in tumorigenesis","volume":"4","author":"Tfelt-Hansen J","year":"2006","unstructured":"Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N: The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res 4:130\u2013137, 20061680940610.3121\/cmr.4.2.130"},{"key":"b57","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","article-title":"Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation","volume":"371","author":"Trivellin G","year":"2014","unstructured":"Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, : Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 371:2363\u20132374, 20142547056910.1056\/NEJMoa1408028"},{"key":"b58","series-title":"Acta Neuropathol","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas J","year":"2013","unstructured":"Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, : A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123\u2013135, 20132340029910.1007\/s00401-013-1084-y"},{"key":"b59","series-title":"Biomed Pharmacother","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.biopha.2017.11.034","article-title":"ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR\/ERK signaling pathway","volume":"97","author":"Wang J","year":"2018","unstructured":"Wang J, Zhang Z, Li R, Mao F, Sun W, Chen J, : ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR\/ERK signaling pathway. Biomed Pharmacother 97:1066\u20131077, 201810.1016\/j.biopha.2017.11.03429136943"},{"key":"b60","series-title":"Biochem Biophys Res Commun","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2019.09.070","article-title":"MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas","volume":"520","author":"Xiao Z","year":"2019","unstructured":"Xiao Z, Wang Z, Hu B, Mao Z, Zhu D, Feng Y, : MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas. Biochem Biophys Res Commun 520:79\u201385, 201910.1016\/j.bbrc.2019.09.07031582213"},{"key":"b61","series-title":"Int J Mol Sci","doi-asserted-by":"publisher","first-page":"E151","DOI":"10.3390\/ijms20010151","article-title":"Biomarker discovery for immunotherapy of pituitary adenomas: enhanced robustness and prediction ability by modern computational tools","volume":"20","author":"Yang Q","year":"2019","unstructured":"Yang Q, Wang Y, Zhang S, Tang J, Li F, Yin J, : Biomarker discovery for immunotherapy of pituitary adenomas: enhanced robustness and prediction ability by modern computational tools. Int J Mol Sci 20:E151, 20193060981210.3390\/ijms20010151"},{"key":"b62","series-title":"Exp Cell Res","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.yexcr.2018.01.008","article-title":"Caveolin-1 promotes pituitary adenoma cells migration and invasion by regulating the interaction between EGR1 and KLF5","volume":"367","author":"Yang W","year":"2018","unstructured":"Yang W, Xu T, Qiu P, Xu G: Caveolin-1 promotes pituitary adenoma cells migration and invasion by regulating the interaction between EGR1 and KLF5. Exp Cell Res 367:7\u201314, 201810.1016\/j.yexcr.2018.01.00829309750"},{"key":"b63","series-title":"Mol Endocrinol","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1210\/mend.13.1.0225","article-title":"Structure, expression, and function of human pituitary tumor-transforming gene (PTTG)","volume":"13","author":"Zhang X","year":"1999","unstructured":"Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, : Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13:156\u2013166, 1999989202110.1210\/mend.13.1.0225"},{"key":"b64","series-title":"Mol Cell Endocrinol","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mce.2013.09.006","article-title":"Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma","volume":"386","author":"Zhou Y","year":"2014","unstructured":"Zhou Y, Zhang X, Klibanski A: Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Mol Cell Endocrinol 386:16\u201333, 201410.1016\/j.mce.2013.09.00624035864"},{"key":"b65","series-title":"J Biol Chem","doi-asserted-by":"publisher","first-page":"24731","DOI":"10.1074\/jbc.M702029200","article-title":"Activation of p53 by MEG3 non-coding RNA","volume":"282","author":"Zhou Y","year":"2007","unstructured":"Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, : Activation of p53 by MEG3 non-coding RNA. J Biol Chem 282:24731\u201324742, 200710.1074\/jbc.M70202920017569660"},{"key":"b1","series-title":"J Neurol Surg B Skull Base","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-0036-1598022","article-title":"Cavernous sinus involvement by pituitary adenomas: clinical implications and outcomes of endoscopic endonasal resection","volume":"78","author":"Ajlan A","year":"2017","unstructured":"Ajlan A, Achrol AS, Albakr A, Feroze AH, Westbroek EM, Hwang P, : Cavernous sinus involvement by pituitary adenomas: clinical implications and outcomes of endoscopic endonasal resection. J Neurol Surg B Skull Base 78:273\u2013282, 201710.1055\/s-0036-159802228603683"},{"key":"b2","series-title":"J Clin Invest","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1172\/JCI114705","article-title":"Clinically nonfunctioning pituitary tumors are monoclonal in origin","volume":"86","author":"Alexander JM","year":"1990","unstructured":"Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A, Klibanski A: Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 86:336\u2013340, 1990197317410.1172\/JCI114705"},{"key":"b3","series-title":"Pituitary","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11102-019-00981-9","article-title":"Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers","volume":"22","author":"Almeida JP","year":"2019","unstructured":"Almeida JP, Stephens CC, Eschbacher JM, Felicella MM, Yuen KCJ, White WL, : Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary 22:514\u2013519, 201910.1007\/s11102-019-00981-9"},{"key":"b4","series-title":"J Clin Endocrinol Metab","first-page":"3210","article-title":"The MEN-1 gene is rarely down-regulated in pituitary adenomas","volume":"83","author":"Asa SL","year":"1998","unstructured":"Asa SL, Somers K, Ezzat S: The MEN-1 gene is rarely down-regulated in pituitary adenomas. J Clin Endocrinol Metab 83:3210\u20133212, 19989745428"},{"key":"b5","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas","volume":"91","author":"Batista DL","year":"2006","unstructured":"Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, : The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482\u20134488, 200610.1210\/jc.2006-124516940446"},{"key":"b6","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1158\/1078-0432.CCR-16-0790","article-title":"Landscape of genomic alterations in pituitary adenomas","volume":"23","author":"Bi WL","year":"2017","unstructured":"Bi WL, Horowitz P, Greenwald NF, Abedalthagafi M, Agarwalla PK, Gibson WJ, : Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res 23:1841\u20131851, 201710.1158\/1078-0432.CCR-16-079027707790"},{"key":"b7","series-title":"Horm Metab Res","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1055\/s-0034-1383566","article-title":"Expression analysis of GADD45\u03b3, MEG3, and p8 in pituitary adenomas","volume":"46","author":"Binse I","year":"2014","unstructured":"Binse I, Ueberberg B, Sandalcioglu IE, Flitsch J, Luedecke DK, Mann K, : Expression analysis of GADD45\u03b3, MEG3, and p8 in pituitary adenomas. Horm Metab Res 46:644\u2013650, 20142512686110.1055\/s-0034-1383566"},{"key":"b8","series-title":"Front Oncol","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fonc.2014.00203","article-title":"Genetically engineered mouse models of pituitary tumors","volume":"4","author":"Cano DA","year":"2014","unstructured":"Cano DA, Soto-Moreno A, Leal-Cerro A: Genetically engineered mouse models of pituitary tumors. Front Oncol 4:203, 201410.3389\/fonc.2014.0020325136513"},{"key":"b9","series-title":"Mol Cell Endocrinol","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2016.10.005","article-title":"Stem cells and their role in pituitary tumorigenesis","volume":"445","author":"Carreno G","year":"2017","unstructured":"Carreno G, Gonzalez-Meljem JM, Haston S, Martinez-Barbera JP: Stem cells and their role in pituitary tumorigenesis. Mol Cell Endocrinol 445:27\u201334, 201710.1016\/j.mce.2016.10.00527720895"},{"key":"b10","series-title":"Ann Endocrinol (Paris)","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ando.2015.04.002","article-title":"Management of clinically non-functioning pituitary adenoma","volume":"76","author":"Chanson P","year":"2015","unstructured":"Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S: Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 76:239\u2013247, 201510.1016\/j.ando.2015.04.002"},{"key":"b11","series-title":"J Transl Med","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s12967-019-02148-3","article-title":"Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles","volume":"17","author":"Cheng S","year":"2019","unstructured":"Cheng S, Xie W, Miao Y, Guo J, Wang J, Li C, : Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles. J Transl Med 17:407, 20193179605210.1186\/s12967-019-02148-3"},{"key":"b12","series-title":"Brain Pathol","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1750-3639.2001.tb00402.x","article-title":"Clonality of pituitary tumours: more complicated than initially envisaged?","volume":"11","author":"Clayton RN","year":"2001","unstructured":"Clayton RN, Farrell WE: Clonality of pituitary tumours: more complicated than initially envisaged? Brain Pathol 11:313\u2013327, 200110.1111\/j.1750-3639.2001.tb00402.x11414474"},{"key":"b13","series-title":"Front Horm Res","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000079045","article-title":"Pituitary tumour clonality revisited","volume":"32","author":"Clayton RN","year":"2004","unstructured":"Clayton RN, Farrell WE: Pituitary tumour clonality revisited. Front Horm Res 32:186\u2013204, 200410.1159\/00007904515281347"},{"key":"b14","series-title":"Clin Cancer Res","first-page":"3973","article-title":"Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins","volume":"6","author":"Clayton RN","year":"2000","unstructured":"Clayton RN, Pfeifer M, Atkinson AB, Belchetz P, Wass JA, Kyrodimou E, : Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins. Clin Cancer Res 6:3973\u20133982, 200011051246"},{"key":"b15","series-title":"Oncotarget","doi-asserted-by":"publisher","first-page":"19674","DOI":"10.18632\/oncotarget.14936","article-title":"O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis","volume":"8","author":"Dai C","year":"2017","unstructured":"Dai C, Sun B, Liu X, Bao X, Feng M, Yao Y, : O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis. Oncotarget 8:19674\u201319683, 201710.18632\/oncotarget.1493628152515"},{"key":"b16","series-title":"Endocr Pathol","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12022-019-09587-0","article-title":"The genomic landscape of sporadic prolactinomas","volume":"30","author":"De Sousa SMC","year":"2019","unstructured":"De Sousa SMC, Wang PPS, Santoreneos S, Shen A, Yates CJ, Babic M, : The genomic landscape of sporadic prolactinomas. Endocr Pathol 30:318\u2013328, 20193147391710.1007\/s12022-019-09587-0"},{"key":"b17","series-title":"Eur J Endocrinol","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange E","year":"2015","unstructured":"Delgrange E, Vasiljevic A, Wierinckx A, Fran\u00e7ois P, Jouanneau E, Raverot G, : Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172:791\u2013801, 20152579237610.1530\/EJE-14-0990"},{"key":"b18","series-title":"Front Neuroendocrinol","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1006\/frne.1999.0195","article-title":"Molecular pathogenesis of pituitary tumors","volume":"21","author":"Farrell WE","year":"2000","unstructured":"Farrell WE, Clayton RN: Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol 21:174\u2013198, 200010.1006\/frne.1999.019510882539"},{"key":"b19","series-title":"Br J Cancer","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/sj.bjc.6690319","article-title":"Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours","volume":"80","author":"Farrell WE","year":"1999","unstructured":"Farrell WE, Simpson DJ, Bicknell J, Magnay JL, Kyrodimou E, Thakker RV, : Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. Br J Cancer 80:44\u201350, 199910.1038\/sj.bjc.669031910389976"},{"key":"b20","series-title":"Clin Endocrinol (Oxf)","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","author":"Fougner SL","year":"2008","unstructured":"Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J: The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 68:458\u2013465, 200810.1111\/j.1365-2265.2007.03065.x"},{"key":"b21","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto F","year":"2013","unstructured":"Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, : Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab 98:E66\u2013E71, 201310.1210\/jc.2012-260923118420"},{"key":"b22","series-title":"Pituitary","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","article-title":"Prevalence and incidence of pituitary adenomas: a population based study in Malta","volume":"16","author":"Gruppetta M","year":"2013","unstructured":"Gruppetta M, Mercieca C, Vassallo J: Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16:545\u2013553, 20132323904910.1007\/s11102-012-0454-0"},{"key":"b23","series-title":"J Endocrinol","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-17-0258","article-title":"Stem\/progenitor cells in pituitary organ homeostasis and tumourigenesis","volume":"236","author":"Haston S","year":"2018","unstructured":"Haston S, Manshaei S, Martinez-Barbera JP: Stem\/progenitor cells in pituitary organ homeostasis and tumourigenesis. J Endocrinol 236:R1\u2013R13, 20182885531610.1530\/JOE-17-0258"},{"key":"b24","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1210\/jcem-71-6-1427","article-title":"Clonal origin of pituitary adenomas","volume":"71","author":"Herman V","year":"1990","unstructured":"Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S: Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71:1427\u20131433, 1990197775910.1210\/jcem-71-6-1427"},{"key":"b25","series-title":"Clin Cancer Res","first-page":"2133","article-title":"Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors","volume":"5","author":"Hibberts NA","year":"1999","unstructured":"Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, : Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res 5:2133\u20132139, 199910473097"},{"key":"b26","series-title":"Eur J Endocrinol","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland LJ","year":"2005","unstructured":"Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, : The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645\u2013654, 20051581792210.1530\/eje.1.01876"},{"key":"b27","series-title":"Cancer Res Treat","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4143\/crt.2016.017","article-title":"Inhibition of SKP2 sensitizes bromocriptine-induced apoptosis in human prolactinoma cells","volume":"49","author":"Huang J","year":"2017","unstructured":"Huang J, Zhang F, Jiang L, Hu G, Sun W, Zhang C, : Inhibition of SKP2 sensitizes bromocriptine-induced apoptosis in human prolactinoma cells. Cancer Res Treat 49:358\u2013373, 201710.4143\/crt.2016.01727488872"},{"key":"b28","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3171\/jns.1990.73.5.0731","article-title":"Clonal origin of pituitary adenomas","volume":"73","author":"Jacoby LB","year":"1990","unstructured":"Jacoby LB, Hedley-Whyte ET, Pulaski K, Seizinger BR, Martuza RL: Clonal origin of pituitary adenomas. J Neurosurg 73:731\u2013735, 1990221316310.3171\/jns.1990.73.5.0731"},{"key":"b29","series-title":"Endocr Relat Cancer","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1530\/ERC-12-0322","article-title":"Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations","volume":"20","author":"Jaffrain-Rea ML","year":"2013","unstructured":"Jaffrain-Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, : Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer 20:753\u2013766, 201310.1530\/ERC-12-032223940012"},{"key":"b30","series-title":"J Endocrinol Invest","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40618-018-0963-4","article-title":"Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1","volume":"42","author":"Jian M","year":"2019","unstructured":"Jian M, Du Q, Zhu D, Mao Z, Wang X, Feng Y, : Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1. J Endocrinol Invest 42:639\u2013652, 201910.1007\/s40618-018-0963-430370446"},{"key":"b31","series-title":"Endocrinol Metab (Seoul)","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3803\/EnM.2013.28.4.245","article-title":"The molecular pathogenesis of pituitary adenomas: an update","volume":"28","author":"Jiang X","year":"2013","unstructured":"Jiang X, Zhang X: The molecular pathogenesis of pituitary adenomas: an update. Endocrinol Metab (Seoul) 28:245\u2013254, 201310.3803\/EnM.2013.28.4.245"},{"key":"b32","series-title":"Pharmacoeconomics","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00019053-200018010-00008","article-title":"The impact of pituitary adenoma on morbidity. Increased sick leave and disability retirement in a cross-sectional analysis of Swedish national data","volume":"18","author":"Jonsson B","year":"2000","unstructured":"Jonsson B, Nilsson B: The impact of pituitary adenoma on morbidity. Increased sick leave and disability retirement in a cross-sectional analysis of Swedish national data. Pharmacoeconomics 18:73\u201381, 200010.2165\/00019053-200018010-00008"},{"key":"b33","series-title":"Endocr Relat Cancer","doi-asserted-by":"publisher","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki L","year":"2012","unstructured":"Kasuki L, Vieira Neto L, Wildemberg LEA, Colli LM, de Castro M, Takiya CM, : AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer 19:L25\u2013L29, 20122242000410.1530\/ERC-12-0020"},{"key":"b34","series-title":"Int J Endocrinol","first-page":"2014","article-title":"MicroRNAs in human pituitary adenomas","volume":"435171","author":"Li XH","year":"2014","unstructured":"Li XH, Wang EL, Zhou HM, Yoshimoto K, Qian ZR: MicroRNAs in human pituitary adenomas. Int J Endocrinol 2014:435171, 2014"},{"key":"b35","series-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd RV","year":"2017","unstructured":"Lloyd RV, Osamura YR, Kloppel G, Rosai J: WHO Classification of Tumours of Endocrine Organs, ed 4. World Health Organization, 2017"},{"key":"b36","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/cncr.10676","article-title":"Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas","volume":"95","author":"Ma W","year":"2002","unstructured":"Ma W, Ikeda H, Yoshimoto T: Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 95:258\u2013266, 200210.1002\/cncr.1067612124824"},{"key":"b37","series-title":"Zhonghua Yi Xue Za Zhi","first-page":"1382","article-title":"[Clinicopathology, clonality, and hormone production profile of prolactinoma.]","volume":"85","author":"Ma WB","year":"2005","unstructured":"Ma WB, Ikeda H, Yoshimoto T: [Clinicopathology, clonality, and hormone production profile of prolactinoma.] Zhonghua Yi Xue Za Zhi 85:1382\u20131387, 2005 (Chinese)16029648"},{"key":"b38","series-title":"Neuropathol Appl Neurobiol","article-title":"Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint","author":"Manojlovic-Gacic E","unstructured":"Manojlovic-Gacic E, Bollerslev J, Casar-Borota O: Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint. Neuropathol Appl Neurobiol [epub ahead of print], 201931112312"},{"key":"b39","series-title":"Nat Rev Endocrinol","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/nrendo.2011.40","article-title":"Pathogenesis of pituitary tumors","volume":"7","author":"Melmed S","year":"2011","unstructured":"Melmed S: Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7:257\u2013266, 20112142324210.1038\/nrendo.2011.40"},{"key":"b40","series-title":"Endocr Pathol","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO Classification of Pituitary Tumors","volume":"28","author":"Mete O","year":"2017","unstructured":"Mete O, Lopes MB: Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol 28:228\u2013243, 20172876605710.1007\/s12022-017-9498-z"},{"key":"b41","series-title":"Pituitary","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11102-011-0340-1","article-title":"Expression of cell growth negative regulators MEG3 and GADD45\u03b3 is lost in most sporadic human pituitary adenomas","volume":"15","author":"Mezzomo LC","year":"2012","unstructured":"Mezzomo LC, Gonzales PH, Pesce FG, Kretzmann Filho N, Ferreira NP, Oliveira MC, : Expression of cell growth negative regulators MEG3 and GADD45\u03b3 is lost in most sporadic human pituitary adenomas. Pituitary 15:420\u2013427, 201210.1007\/s11102-011-0340-121850407"},{"key":"b42","series-title":"Front Horm Res","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000079037","article-title":"Cell cycle dysregulation in pituitary oncogenesis","volume":"32","author":"Mu\u015fat M","year":"2004","unstructured":"Mu\u015fat M, Vax VV, Borboli N, Gueorguiev M, Bonner S, Korbonits M, : Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res 32:34\u201362, 200410.1159\/00007903715281339"},{"key":"b43","series-title":"Brain Tumor Pathol","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10014-017-0307-7","article-title":"New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors","volume":"35","author":"Nishioka H","year":"2018","unstructured":"Nishioka H, Inoshita N: New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol 35:57\u201361, 20182931839610.1007\/s10014-017-0307-7"},{"key":"b44","series-title":"J Neuropathol Exp Neurol","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/jnen\/64.5.398","article-title":"The p15INK4b\/p16INK4a\/RB1 pathway is frequently deregulated in human pituitary adenomas","volume":"64","author":"Ogino A","year":"2005","unstructured":"Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, : The p15INK4b\/p16INK4a\/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 64:398\u2013403, 200510.1093\/jnen\/64.5.398"},{"key":"b45","series-title":"Front Horm Res","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000079036","article-title":"Molecular pathology of the pituitary. Development and functional differentiation of pituitary adenomas","volume":"32","author":"Osamura RY","year":"2004","unstructured":"Osamura RY, Egashira N, Miyai S, Yamazaki M, Takekoshi S, Sanno N, : Molecular pathology of the pituitary. Development and functional differentiation of pituitary adenomas. Front Horm Res 32:20\u201333, 200410.1159\/00007903615281338"},{"key":"b46","series-title":"Histochem Cell Biol","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00418-008-0472-1","article-title":"Pathology of the human pituitary adenomas","volume":"130","author":"Osamura RY","year":"2008","unstructured":"Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, : Pathology of the human pituitary adenomas. Histochem Cell Biol 130:495\u2013507, 20081868863610.1007\/s00418-008-0472-1"},{"key":"b47","series-title":"Endocrine","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","article-title":"Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial","volume":"57","author":"Petersenn S","year":"2017","unstructured":"Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, : Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 57:156\u2013165, 20172859719810.1007\/s12020-017-1316-3"},{"key":"b48","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1210\/jcem.83.4.4859","article-title":"Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors","volume":"83","author":"Prezant TR","year":"1998","unstructured":"Prezant TR, Levine J, Melmed S: Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab 83:1388\u20131391, 1998954317210.1210\/jcem.83.4.4859"},{"key":"b49","series-title":"Nat Genet","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease","volume":"47","author":"Reincke M","year":"2015","unstructured":"Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, : Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet 47:31\u201338, 20152548583810.1038\/ng.3166"},{"key":"b50","series-title":"Eur J Endocrinol","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-15-1064","article-title":"Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas","volume":"174","author":"Ronchi CL","year":"2016","unstructured":"Ronchi CL, Peverelli E, Herterich S, Weigand I, Mantovani G, Schwarzmayr T, : Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 174:363\u2013372, 201610.1530\/EJE-15-106426701869"},{"key":"b51","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/1078-0432.CCR-17-2206","article-title":"The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing\u2019s disease and endocrine-inactive subtypes","volume":"24","author":"Salomon MP","year":"2018","unstructured":"Salomon MP, Wang X, Marzese DM, Hsu SC, Nelson N, Zhang X, : The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing\u2019s disease and endocrine-inactive subtypes. Clin Cancer Res 24:4126\u20134136, 201810.1158\/1078-0432.CCR-17-220630084836"},{"key":"b52","series-title":"J Clin Endocrinol Metab","first-page":"1675","article-title":"Genetic basis of endocrine disease: pituitary tumor pathogenesis","volume":"82","author":"Shimon I","year":"1997","unstructured":"Shimon I, Melmed S: Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab 82:1675\u20131681, 19979177361"},{"key":"b53","series-title":"Carcinogenesis","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/carcin\/22.8.1149","article-title":"Aberrant expression of G1\/S regulators is a frequent event in sporadic pituitary adenomas","volume":"22","author":"Simpson DJ","year":"2001","unstructured":"Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN, : Aberrant expression of G1\/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 22:1149\u20131154, 200110.1093\/carcin\/22.8.1149"},{"key":"b54","series-title":"Int J Oncol","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3892\/ijo.2017.4120","article-title":"Trophic and neurotrophic factors in human pituitary adenomas (Review)","volume":"51","author":"Spoletini M","year":"2017","unstructured":"Spoletini M, Taurone S, Tombolini M, Minni A, Altissimi G, Wierzbicki V, : Trophic and neurotrophic factors in human pituitary adenomas (Review). Int J Oncol 51:1014\u20131024, 20172890235010.3892\/ijo.2017.4120"},{"key":"b55","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1023\/A:1010655419332","article-title":"Genetic basis of pituitary adenoma invasiveness: a review","volume":"52","author":"Suhardja A","year":"2001","unstructured":"Suhardja A, Kovacs K, Rutka J: Genetic basis of pituitary adenoma invasiveness: a review. J Neurooncol 52:195\u2013204, 200110.1023\/A:101065541933211519849"},{"key":"b56","series-title":"Clin Med Res","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3121\/cmr.4.2.130","article-title":"The emerging role of pituitary tumor transforming gene in tumorigenesis","volume":"4","author":"Tfelt-Hansen J","year":"2006","unstructured":"Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N: The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res 4:130\u2013137, 20061680940610.3121\/cmr.4.2.130"},{"key":"b57","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","article-title":"Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation","volume":"371","author":"Trivellin G","year":"2014","unstructured":"Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, : Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 371:2363\u20132374, 20142547056910.1056\/NEJMoa1408028"},{"key":"b58","series-title":"Acta Neuropathol","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas J","year":"2013","unstructured":"Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, : A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123\u2013135, 20132340029910.1007\/s00401-013-1084-y"},{"key":"b59","series-title":"Biomed Pharmacother","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.biopha.2017.11.034","article-title":"ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR\/ERK signaling pathway","volume":"97","author":"Wang J","year":"2018","unstructured":"Wang J, Zhang Z, Li R, Mao F, Sun W, Chen J, : ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR\/ERK signaling pathway. Biomed Pharmacother 97:1066\u20131077, 201810.1016\/j.biopha.2017.11.03429136943"},{"key":"b60","series-title":"Biochem Biophys Res Commun","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2019.09.070","article-title":"MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas","volume":"520","author":"Xiao Z","year":"2019","unstructured":"Xiao Z, Wang Z, Hu B, Mao Z, Zhu D, Feng Y, : MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas. Biochem Biophys Res Commun 520:79\u201385, 201910.1016\/j.bbrc.2019.09.07031582213"},{"key":"b61","series-title":"Int J Mol Sci","doi-asserted-by":"publisher","first-page":"E151","DOI":"10.3390\/ijms20010151","article-title":"Biomarker discovery for immunotherapy of pituitary adenomas: enhanced robustness and prediction ability by modern computational tools","volume":"20","author":"Yang Q","year":"2019","unstructured":"Yang Q, Wang Y, Zhang S, Tang J, Li F, Yin J, : Biomarker discovery for immunotherapy of pituitary adenomas: enhanced robustness and prediction ability by modern computational tools. Int J Mol Sci 20:E151, 20193060981210.3390\/ijms20010151"},{"key":"b62","series-title":"Exp Cell Res","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.yexcr.2018.01.008","article-title":"Caveolin-1 promotes pituitary adenoma cells migration and invasion by regulating the interaction between EGR1 and KLF5","volume":"367","author":"Yang W","year":"2018","unstructured":"Yang W, Xu T, Qiu P, Xu G: Caveolin-1 promotes pituitary adenoma cells migration and invasion by regulating the interaction between EGR1 and KLF5. Exp Cell Res 367:7\u201314, 201810.1016\/j.yexcr.2018.01.00829309750"},{"key":"b63","series-title":"Mol Endocrinol","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1210\/mend.13.1.0225","article-title":"Structure, expression, and function of human pituitary tumor-transforming gene (PTTG)","volume":"13","author":"Zhang X","year":"1999","unstructured":"Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, : Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13:156\u2013166, 1999989202110.1210\/mend.13.1.0225"},{"key":"b64","series-title":"Mol Cell Endocrinol","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mce.2013.09.006","article-title":"Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma","volume":"386","author":"Zhou Y","year":"2014","unstructured":"Zhou Y, Zhang X, Klibanski A: Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Mol Cell Endocrinol 386:16\u201333, 201410.1016\/j.mce.2013.09.00624035864"},{"key":"b65","series-title":"J Biol Chem","doi-asserted-by":"publisher","first-page":"24731","DOI":"10.1074\/jbc.M702029200","article-title":"Activation of p53 by MEG3 non-coding RNA","volume":"282","author":"Zhou Y","year":"2007","unstructured":"Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, : Activation of p53 by MEG3 non-coding RNA. J Biol Chem 282:24731\u201324742, 200710.1074\/jbc.M70202920017569660"}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/48\/6\/article-pE11.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/48\/6\/article-pE11.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/48\/6\/article-pE11.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:39:00Z","timestamp":1778315940000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/48\/6\/article-pE11.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":130,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2020.3.focus20104","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}